Comparing low dose and standard liver CT scans for colorectal cancer patients
Comparison of Image Quality Between "Double Low Dose" Liver CT Using AI-based Iodine Boosting Reconstruction and Standard Contrast-enhanced Liver CT in Patients With Colorectal Cancer: Prospective, Randomized, Non-inferiority Trial
This study is testing whether a lower dose of a special liver CT scan can give good enough images for people with colorectal cancer that have spread to the liver, while using less radiation than the standard dose.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 176 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05790590 on ClinicalTrials.gov |
What this trial studies
This study investigates the feasibility of using a 'double low dose' contrast-enhanced abdominal CT in patients with liver metastases from colorectal cancer. It employs artificial intelligence-based noise reduction and contrast enhancement software to potentially improve image quality while reducing radiation exposure. The study compares the image quality of this low dose CT against standard dose CT in monitoring cancer recurrence and treatment response. The goal is to determine if the lower dose can provide adequate imaging for clinical decision-making.
Who should consider this trial
Good fit: Ideal candidates are colorectal cancer patients undergoing surveillance for liver metastases.
Not a fit: Patients with contraindications to contrast-enhanced CT or those with diffuse infiltrative liver metastasis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could reduce radiation exposure for patients while maintaining or improving the quality of imaging for liver metastases.
How similar studies have performed: Other studies have shown promise in using low dose CT techniques, but this specific approach with AI-based enhancements is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * colorectal cancer (CRC) patients * on surveillance or monitoring for liver metastasis (of CRC) Exclusion Criteria: * any relative or absolute contra-indication of CECT * diffuse infiltrative type of liver metastasis or on monitoring for too many liver lesions
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Jeong Min Lee, MD — Seoul National University Hospital
- Study coordinator: Hyuna Jung
- Email: jha5375@snu.ac.kr
- Phone: 82-2-2072-4177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.